Welcome to our dedicated page for Gamida Cell Ltd. news (Ticker: GMDA), a resource for investors and traders seeking the latest updates and insights on Gamida Cell Ltd. stock.
Gamida Cell Ltd. (NASDAQ: GMDA) is a clinical-stage biotech company advancing NAM-enabled cell therapies for blood cancers and genetic disorders. This page provides official updates on clinical trials, regulatory milestones, and strategic initiatives.
Access timely announcements about Gamida Cell’s pipeline progress, including allogeneic cell therapy developments and FDA-designated programs. Investors will find earnings reports, partnership details, and operational updates essential for tracking the company’s position in the immunotherapy sector.
Key content includes clinical data disclosures, manufacturing advancements, and scientific presentations. All materials are sourced directly from company filings and verified channels to ensure reliability.
Bookmark this page for structured access to Gamida Cell’s latest developments in cellular immunotherapy and rare disease research. Check regularly for updates on their NAM technology applications and therapeutic pipeline progress.
Gamida Cell Ltd. (Nasdaq: GMDA) announced the pricing of a public offering of 17,500,000 ordinary shares along with warrants for gross proceeds of approximately $22.8 million at a price of $1.30 per share. The warrants, with an exercise price of $1.35, are immediately exercisable and will expire in five years. The offering closing is expected on April 21, 2023, pending customary conditions. The company plans to utilize the net proceeds for the commercialization of Omisirge®, continued development of GDA-201, and general corporate purposes. An additional 2,625,000 shares may be purchased by underwriters within 30 days of the offering. A registration statement has been filed and became effective on April 1, 2022.
Gamida Cell Ltd. (Nasdaq: GMDA) announced a follow-on public offering of its ordinary shares and accompanying warrants, with the potential for underwriters to purchase an additional 15%. The offering is contingent on market conditions, and no completion guarantee is provided. Proceeds will support commercial activities for Omisirge®, continued clinical development of GDA-201, and general corporate purposes. The registration statement for the shares was previously filed and became effective on April 1, 2022. The offering is managed by Piper Sandler & Co..
Gamida Cell Ltd. announces FDA approval of Omisirge (omidubicel-onlv), an allogeneic cell therapy for adult and pediatric patients 12 years and older with hematologic malignancies. This approval is based on a global randomized Phase 3 clinical trial demonstrating significant benefits, including a median time to neutrophil recovery of 12 days versus 22 days for standard cord blood (p<0.001). Furthermore, Omisirge showed a reduced incidence of severe infections (39% vs. 60%). With breakthrough therapy designation and orphan drug designation, Omisirge potentially increases access to transplants, particularly for racially diverse patients. The company is actively onboarding transplant centers and pursuing strategic partnerships for commercialization. A conference call is scheduled for April 18 at 8 am ET.
FAQ
What is the market cap of Gamida Cell Ltd. (GMDA)?
